Genmab winds down zalutumumab in absence of partner
This article was originally published in Scrip
Executive Summary
Genmab is to wind down its development programme for the anticancer antibody zalutumumab after failing to secure a partnership deal. The company had given itself a six-month deadline to secure a partner or cease further investment in the product, and although it was in talks right up to the last moment, felt that the discussions were not going to lead to a satisfactory partnership, it told Scrip.